These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1079 related articles for article (PubMed ID: 16442246)

  • 21. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The match between adhesive mixture powder formulations for inhalation and the inhaler device.
    Thalberg K; Ahmadi R; Stuckel J; Elfman P; Svensson M
    Eur J Pharm Sci; 2023 Jul; 186():106457. PubMed ID: 37116546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
    Fyrnys B; Stang N; Wolf-Heuss E
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
    Handoko A; Ian L; Peter SJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):265-74. PubMed ID: 18996188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
    AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
    Thi TH; Danède F; Descamps M; Flament MP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do all dry powder inhalers show the same pharmaceutical performance?
    Taylor A; Gustafsson P
    Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Kussendrager KD; Frijlink HW
    Int J Pharm; 2003 Jul; 260(2):201-16. PubMed ID: 12842340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation.
    Sebti T; Amighi K
    Eur J Pharm Biopharm; 2006 May; 63(1):51-8. PubMed ID: 16380243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhalation performance of pollen-shape carrier in dry powder formulation: effect of size and surface morphology.
    Hassan MS; Lau R
    Int J Pharm; 2011 Jul; 413(1-2):93-102. PubMed ID: 21540087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP; Marriott C; Zeng XM
    Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.